Skip to main content
Premium Trial:

Request an Annual Quote

Helomics Precision Oncology Insights Program

Helomics announced that it has launched its new Precision Oncology Insights platform, which provides a personalized oncology roadmap for oncologists and their patients. Having agreed to be acquired by Precision Therapeutics in June, Helomics will offer the platform as a tool to test living tumor tissue from the patient to determine how the tumors respond to drugs. Helomics then integrates the drug response with other genomic and molecular data. The firm's artificial intelligence knowledge base, D-CHIP (Dynamic Clinical Health Insights), then analyzes the data to generate a roadmap that provides additional context to help personalize patient treatment.